10-QFiled 5 Nov 2026All industries
Goodyear Tire & Rubber Co /Oh/GT
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
The nightly ledger
Every 8-K, 10-Q and 10-K that AIR's companies filed on SEC EDGAR, and what each one changed in AIR's read. Material filings first, newest first — never ordered by price. For 8-K filing alerts, follow a company and turn on filing emails.
By event type: Acquisitions · Major contracts
Seven-day window, 2 weeks back · Material filings: 1629 · All filings: 1839
Thursday 5 Nov642 filings read · 590 material
10-QFiled 5 Nov 2026All industries
Goodyear Tire & Rubber Co /Oh/GT
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
10-QFiled 5 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
The price trend strengthened.
10-QFiled 5 Nov 2026Banks
Bancorp, Inc.TBBK
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
10-QFiled 5 Nov 2026All industries
BKV CorpBKV
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
8-KFiled 5 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Q3 2026 revenue of $91M (+34% YoY) exceeded expectations; gross margin expanded to 76%; net income $7M vs. loss of $3M prior year. Total members reached 1.1M (+36% YoY). Full-year 2026 guidance raised significantly.
Market attention has faded.
Progress is running ahead of attention.
The price trend weakened.
8-KFiled 5 Nov 2026All industries
8-K · Item 2.02 — Results of operations
HNST reported Q3 2026 results with 9.2% organic revenue growth, record 48.9% adjusted gross margin (+1,160 bps YoY), and raised FY2026 guidance. Company approved $30M share repurchase and generated $30.5M free cash flow YTD.
No notable change in AIR's read.
8-KFiled 5 Nov 2026All industries
8-K · Items 2.02, 8.01 — Results of operations
Q3 2026 revenue grew 9.5% YoY to $1.57B; comparable restaurant sales increased 4.3%; diluted EPS rose 8.6% to $1.36. Board approved $0.75/share quarterly dividend. Management guides positive comp sales for 2027 with 5-6% store growth.
The shares became dearer on AIR's value read.
Progress is running ahead of attention.
The price trend strengthened.
8-KFiled 5 Nov 2026Biotech
Ginkgo Bioworks Holdings, Inc.DNA
8-K · Item 2.02 — Results of operations
Ginkgo reported Q3 2026 revenue of $28M (flat YoY), improved net loss to ($41)M from ($73)M YoY, and announced first autonomous lab sale to Novo pharma plus $17.5M ARPA-H subcontract and NSF/X-Labs partnerships.
More of the market is starting to notice.
The price trend strengthened.
10-QFiled 5 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
8-KFiled 5 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Century Aluminum reported Q3 2026 net income of $302.6M (+21% QoQ), driven by Line 2 restart at Grundartangi facility reaching near-full production and favorable metal prices. Adjusted EBITDA $331.6M (+1.4% QoQ); Q4 guidance $275–300M.
Progress is running ahead of attention.
The price trend strengthened.
8-KFiled 5 Nov 2026Biotech
Palvella Therapeutics, Inc.PVLA
8-K · Item 2.02 — Results of operations
FDA accepted NDA for QTORIN rapamycin in microcystic lymphatic malformations with Priority Review; PDUFA target date February 28, 2027. Company advancing commercial launch preparations for H1 2027 if approved. Strong cash position of $236.7M.
More of the market is starting to notice.
Progress is running ahead of attention.
The price trend strengthened.
8-KFiled 5 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Castle Biosciences reported Q3 2026 revenue of $102.9M (+24% YoY), driven by 47% growth in TissueCypher test volume. Company raised full-year 2026 revenue guidance to $385–395M from $365–375M and maintains positive Adjusted EBITDA expectations.
Progress is running ahead of attention.
The price trend weakened.
8-KFiled 5 Nov 2026Industrials
8-K · Items 2.02, 8.01 — Results of operations
Q3 2026 revenue declined 5.4% YoY to $319.7M. Despite improved profitability metrics, company revised full-year adjusted EBITDA guidance downward to $180–200M from prior expectations, citing customer demand pushed into 2027 and memory chip pressures.
Market attention has faded.
The shares became cheaper on AIR's value read.
The gap narrowed as the filings read less positively.
The price trend weakened.
10-QFiled 5 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
The price trend strengthened.
8-KFiled 5 Nov 2026Software / SaaS
8-K · Item 2.02 — Results of operations
Teradata reported Q3 2026 results with modest ARR growth (1% YoY, 2% constant currency) and strong public cloud ARR growth (11%), but total revenue declined 4% YoY. Company narrowed full-year revenue guidance to high-end of range and reaffirmed ARR and free cash flow targets. Q4 guidance shows revenue decline.
Market attention has faded.
The price trend strengthened.
8-KFiled 5 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Q3 2026: Normalized FFO/FAD per share up 20% YoY to $0.54/$0.53. Company raised full-year 2026 guidance (FFO +18.5%, FAD +16.2% vs 2025). Closed $733M of $1.1B LNT UK care homes acquisition; $2.9B invested YTD at 8.1% yield. Leverage 1.4x, well below 4-5x target.
Progress is running ahead of attention.
10-QFiled 5 Nov 2026All industries
GRAIL, Inc.GRAL
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
10-QFiled 5 Nov 2026Industrials
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
The price trend strengthened.
8-KFiled 5 Nov 2026Industrials
8-K · Items 2.02, 8.01 — Results of operations
Q3 2026 revenue of $763.7M declined 0.7% YoY; company lowered full-year 2026 guidance to $3.09B (5.1% growth) from prior range of $3.18–$3.22B. International sales fell 5.7%. Base business grew 3.0%, but overall results missed expectations.
The shares became cheaper on AIR's value read.
Attention caught up with the documented progress.
The price trend weakened.
8-KFiled 5 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Green Plains reported Q3 2026 net income of $85.4M ($1.03 EPS) vs. $11.9M ($0.17 EPS) prior year. Record adjusted EBITDA of $118.0M driven by 45Z tax credits and improved crush margins. Executed $250–325M 45Z monetization agreement.
Progress is running ahead of attention.
The price trend weakened.
10-QFiled 5 Nov 2026All industries
FIGS, Inc.FIGS
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
8-KFiled 5 Nov 2026All industries
8-K · Items 2.02, 8.01 — Results of operations
A10 Networks reported Q3 2026 revenue of $91.5M (+22.6% YoY), beating prior guidance. Full-year revenue guidance raised to ~16% growth from 12-14%. Non-GAAP EPS guidance increased to $1.08-$1.10 (20-22% growth). Board approved $0.06/share quarterly dividend.
The shares became dearer on AIR's value read.
Progress is running ahead of attention.
The price trend strengthened.
8-KFiled 5 Nov 2026Semiconductors
8-K · Item 2.02 — Results of operations
Q3 2026: Revenue $25.8M (+48% YoY), ACV+royalties $103.8M (+39% YoY), RPO $135.5M (+29% YoY). Surpassed 1,000 design starts milestone. Major deals with hyperscaler, semiconductor leaders, automotive OEM. FY2026 revenue guidance raised to $98.5–$99.5M.
The shares became dearer on AIR's value read.
Progress is running ahead of attention.
The price trend weakened.
10-QFiled 5 Nov 2026All industries
Power Solutions International, Inc.PSIX
Quarterly report (10-Q), period ending 30 Sep 2026
Market attention has faded.
The shares became cheaper on AIR's value read.
The price trend weakened.
10-QFiled 5 Nov 2026Semiconductors
Quarterly report (10-Q), period ending 3 Oct 2026
Progress is running ahead of attention.
The price trend weakened.
8-KFiled 5 Nov 2026All industries
Power Solutions International, Inc.PSIX
8-K · Item 2.02 — Results of operations
Market attention has faded.
The shares became cheaper on AIR's value read.
The price trend weakened.
8-KFiled 5 Nov 2026All industries
Abacus Global Management, Inc.ABX
8-K · Items 2.02, 8.01 — Results of operations
Abacus reported record Q3 2026 revenue of $76.9M (+22% YoY), adjusted net income of $29.4M exceeding guidance, and raised full-year 2026 adjusted net income guidance to $104.5–$106.5M (up to 24% YoY). Longevity fund inflows surged to $452.4M; completed $400M securitization; declared $0.22 annual dividend.
The gap narrowed — attention is catching up.
The price trend strengthened.
8-KFiled 5 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Camden Property Trust reported Q3 2026 results with same-property NOI declining 0.2% YoY and 1.5% sequentially. Core FFO guidance for 2026 held flat, but full-year NOI guidance reduced to -1.5% to -0.5% from prior -0.6%. Effective new lease rates declined 2.0%.
No notable change in AIR's read.
10-QFiled 5 Nov 2026Banks
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
The price trend weakened.
10-QFiled 5 Nov 2026Semiconductors
Quarterly report (10-Q), period ending 30 Sep 2026
The shares became dearer on AIR's value read.
Progress is running ahead of attention.
The price trend weakened.
10-QFiled 5 Nov 2026Industrials
Quarterly report (10-Q), period ending 30 Sep 2026
The shares became cheaper on AIR's value read.
Attention caught up with the documented progress.
The price trend weakened.
10-QFiled 5 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
The price trend strengthened.
10-QFiled 5 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
The price trend weakened.
10-QFiled 5 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
The shares became cheaper on AIR's value read.
10-QFiled 5 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
The price trend weakened.
10-QFiled 5 Nov 2026All industries
Lemonade, Inc.LMND
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
8-KFiled 5 Nov 2026All industries
Ecovyst Inc.ECVT
8-K · Item 2.02 — Results of operations
Ecovyst reported Q3 2026 results beating guidance with 51% sales growth to $308.6M and Adjusted EBITDA of $61.2M (+6% YoY). Company raised full-year 2026 Adjusted EBITDA guidance to $208–212M from $195–207M, citing strong refining margins, export demand, and successful Calabrian integration.
No notable change in AIR's read.
10-QFiled 5 Nov 2026Biotech
Eton Pharmaceuticals, Inc.ETON
Quarterly report (10-Q), period ending 30 Sep 2026
The shares became cheaper on AIR's value read.
The gap narrowed — attention is catching up.
The price trend strengthened.
8-KFiled 5 Nov 2026All industries
Core Natural Resources, Inc.CNR
8-K · Item 2.02 — Results of operations
CNR reported Q3 2026 net income of $9.0M ($0.18/share) and adjusted EBITDA of $165.2M on $1.1B revenue. Company returned $90M to shareholders, repurchased 930k shares, and secured ~29M tons of future sales commitments at improved prices amid strengthening thermal and metallurgical coal markets.
No notable change in AIR's read.
10-QFiled 5 Nov 2026Software / SaaS
IBEX LtdIBEX
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
The price trend strengthened.
8-KFiled 5 Nov 2026All industries
Northwest Natural Holding CoNWN
8-K · Item 2.02 — Results of operations
NW Natural raised 2026 EPS guidance to $3.10–$3.20 from $2.95–$3.15, driven by strong year-to-date performance, constructive regulatory outcomes in Washington and Oregon, and SiEnergy settlement in Texas. Announced 71st consecutive dividend increase, largest since 2012.
More of the market is starting to notice.
The shares became dearer on AIR's value read.
The price trend strengthened.
10-QFiled 5 Nov 2026All industries
Northwest Natural Holding CoNWN
Quarterly report (10-Q), period ending 30 Sep 2026
More of the market is starting to notice.
The shares became dearer on AIR's value read.
The price trend strengthened.
8-KFiled 5 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Arlo reported Q3 2026 results with record subscriptions revenue of $96M (+20% YoY), ARR of $370M (+14% YoY), gross margin expansion of 600bps, adjusted EBITDA up 57.6% YoY, and authorized a new $100M share repurchase program.
Progress is running ahead of attention.
The price trend weakened.
10-QFiled 5 Nov 2026All industries
Quarterly report (10-Q), period ending 27 Sep 2026
Progress is running ahead of attention.
The price trend weakened.
10-QFiled 5 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
More of the market is starting to notice.
Progress is running ahead of attention.
The price trend strengthened.
8-KFiled 5 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Q3 2026 revenue grew 3% to $685M with adjusted EPS up 40% to $1.50. Full-year adjusted EPS raised to $5.40 (31% growth). Lee divestiture completed for $698M net proceeds; $450M share repurchase planned. 2027 EPS guidance of at least $6.60 (20%+ growth).
More of the market is starting to notice.
Progress is running ahead of attention.
The price trend strengthened.
10-QFiled 5 Nov 2026All industries
Quarterly report (10-Q), period ending 3 Oct 2026
More of the market is starting to notice.
Progress is running ahead of attention.
The price trend strengthened.
10-QFiled 5 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
The gap narrowed — attention is catching up.
The price trend strengthened.
8-KFiled 5 Nov 2026Biotech
Iovance Biotherapeutics, Inc.IOVA
8-K · Item 2.02 — Results of operations
Q3 2026 revenue reached record ~$122M (+80% YoY), gross margin improved to ~60%, Amtagvi exceeded 1,000 treated patients. Multiple clinical trials show strong efficacy: 24.6% ORR in mNSCLC, 59.1% in biomarker-selected subset, 55.6% in UPS/DDLPS. Company reaffirms FY2026 guidance of $410–$420M revenue.
The shares became cheaper on AIR's value read.
Progress is running ahead of attention.
The price trend weakened.
8-KFiled 5 Nov 2026Biotech
Aclaris Therapeutics, Inc.ACRS
8-K · Item 2.02 — Results of operations
Aclaris reported positive Phase 1b results for ATI-052 in atopic dermatitis and asthma, initiated Phase 2b trials for modzatinib in lichen planus, and reaffirmed bosakitug Phase 2 timeline. Cash runway extended to H1 2029 via $50M October offering.
Progress is running ahead of attention.
10-QFiled 5 Nov 2026Biotech
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
8-KFiled 5 Nov 2026All industries
Cogent Communications Holdings, Inc.CCOI
8-K · Item 2.02 — Results of operations
Q3 2026 service revenue declined 1.8% QoQ and 4.4% YoY to $231.2M. Off-net revenue fell 9.3% QoQ. Board suspended dividend program. Partially offset by wavelength revenue growth (+7.8% QoQ, +57% YoY) and adjusted EBITDA margin expansion to 32.0%.
No notable change in AIR's read.
8-KFiled 5 Nov 2026All industries
International Seaways, Inc.INSW
8-K · Item 2.02 — Results of operations
Q3 2026 record net income of $344M ($6.90/share), driven by exceptional tanker market conditions and higher spot earnings. Fleet expansion via Bruton acquisition, strong free cash flow of $234M, and record $5.05/share dividend declared.
The filings read more positively.
Market attention has faded.
Progress is running ahead of attention.
The price trend weakened.
8-KFiled 5 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Q3 2026: Revenue $276.9M (+2% YoY), volume $25.3B (+13% YoY), B2B volume surged 59% YoY. ARPU grew 18% YoY. Shareholder approved Nuvei merger; targeting mid-2027 close. Obtained payment licenses in Canada and Israel.
No notable change in AIR's read.
8-KFiled 5 Nov 2026Biotech
8-K · Items 1.01, 1.02 — Material agreement
Avalo entered into an at-the-market offering agreement with Jefferies for up to $200M in common stock sales and terminated its prior TD Cowen sales agreement. No immediate capital raise or business impact disclosed.
No notable change in AIR's read.
8-KFiled 5 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Q3 2026 revenue of $237.8M exceeded expectations with 11.2% YoY growth. Strong bookings reflect broadening recovery across Memory, Power, and General Mature end markets. Record CS&I revenue and healthy cash generation support positive 2027 outlook.
Progress is running ahead of attention.
The price trend strengthened.
10-QFiled 5 Nov 2026Biotech
Corvus Pharmaceuticals, Inc.CRVS
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
The price trend strengthened.
10-QFiled 5 Nov 2026Biotech
Celldex Therapeutics, Inc.CLDX
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
8-KFiled 5 Nov 2026Software / SaaS
Innodata IncINOD
8-K · Item 2.02 — Results of operations
Market attention has faded.
Progress is running ahead of attention.
The price trend weakened.
8-KFiled 5 Nov 2026All industries
Opendoor Technologies Inc.OPEN
8-K · Item 2.02 — Results of operations
Opendoor reported Q3 2026 revenue of $1,022M (+12% YoY), homes purchased quadrupled to 4,865 (+316% YoY), market share increased 4.4x to 0.56%, and trailing-twelve-month marketing and operations efficiency improved 57% and 36% respectively.
The shares became dearer on AIR's value read.
Progress is running ahead of attention.
8-KFiled 5 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Astrana Health reported Q3 2026 record revenue of $1,023.6M (+7% YoY), record adjusted EBITDA of $77.2M (+13% YoY), and net income of $20.3M (+1,782% YoY). Nine-month results show 33% revenue growth and 39% adjusted EBITDA growth with $105.4M free cash flow.
Market attention has faded.
The shares became cheaper on AIR's value read.
The price trend weakened.
10-QFiled 5 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
The price trend strengthened.
8-KFiled 5 Nov 2026Biotech
Rezolute, Inc.RZLT
8-K · Item 2.02 — Results of operations
Rezolute reported Q1 FY2027 results with enrollment completion in Phase 3 upLIFT tumor HI study (topline mid-December 2026), 7 of 8 early participants met primary endpoint, and FDA recommended BLA filing for congenital HI despite prior primary endpoint miss.
Progress is running ahead of attention.
The price trend weakened.
8-KFiled 5 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Q3 2026 revenue of $112.2M (+5.7% YoY) with net loss of $5.7M vs. $23.8M loss prior year. Adjusted EBITDA $27.2M (+57% YoY). Raised full-year EBITDA guidance to $75–80M. RNG volumes +9%, new hydrogen contract, tax credit monetization.
More of the market is starting to notice.
Progress is running ahead of attention.
The price trend strengthened.
10-QFiled 5 Nov 2026Biotech
Aclaris Therapeutics, Inc.ACRS
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
8-KFiled 5 Nov 2026Software / SaaS
8-K · Item 2.02 — Results of operations
Unity achieved Q3 2026 record revenue of $622M (+32% YoY), first GAAP profitable quarter since IPO with $122M net income, and Vector grew 126% YoY. Strategic revenue up 59% YoY; Adjusted EBITDA $257M (+136% YoY). Q4 guidance projects 65-67% Strategic revenue growth.
More of the market is starting to notice.
The shares became dearer on AIR's value read.
The price trend strengthened.
10-QFiled 5 Nov 2026Industrials
Redwire CorpRDW
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
The price trend weakened.
10-QFiled 5 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
Market attention has faded.
The price trend weakened.
10-QFiled 5 Nov 2026Software / SaaS
Innodata IncINOD
Quarterly report (10-Q), period ending 30 Sep 2026
Market attention has faded.
Progress is running ahead of attention.
The price trend weakened.
10-QFiled 5 Nov 2026All industries
Deluxe CorpDLX
Quarterly report (10-Q), period ending 30 Sep 2026
More of the market is starting to notice.
The shares became dearer on AIR's value read.
The price trend strengthened.
10-QFiled 5 Nov 2026Software / SaaS
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
8-KFiled 5 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Krispy Kreme reported Q3 2026 results showing improved profitability metrics, increased revenue guidance, reduced leverage, and strong free cash flow improvement. Systemwide sales grew 1.0% in constant currency despite 12.4% net revenue decline from refranchising.
More of the market is starting to notice.
The price trend strengthened.
10-QFiled 5 Nov 2026All industries
Quarterly report (10-Q), period ending 27 Sep 2026
More of the market is starting to notice.
The price trend strengthened.
10-QFiled 5 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
8-KFiled 5 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Q3 2026 net sales grew 8.5% to $463.1M with comp-store sales up 4.2%. Net income $23.4M ($0.15/share); Adjusted EBITDA $75.9M (16.4% margin), marking fourth consecutive quarter of YoY growth. Company raised FY2026 comparable store sales and Adjusted EBITDA guidance.
More of the market is starting to notice.
Progress is running ahead of attention.
The price trend strengthened.
8-KFiled 5 Nov 2026Biotech
Amphastar Pharmaceuticals, Inc.AMPH
8-K · Item 2.02 — Results of operations
Amphastar reported Q3 2026 net revenues of $207.6M (+8% YoY), GAAP net income of $37.8M (+118% YoY), and adjusted non-GAAP EPS of $1.14 (+22% YoY). Record BAQSIMI and Primatene MIST sales offset declines in epinephrine and glucagon. Gross margin compressed to 48% from 51.4% due to pricing pressure and manufacturing remediation costs.
More of the market is starting to notice.
The price trend strengthened.
10-QFiled 5 Nov 2026Biotech
Amphastar Pharmaceuticals, Inc.AMPH
Quarterly report (10-Q), period ending 30 Sep 2026
More of the market is starting to notice.
The price trend strengthened.
10-QFiled 5 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
Market attention has faded.
The shares became dearer on AIR's value read.
10-QFiled 5 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
Market attention has faded.
The price trend weakened.
8-KFiled 5 Nov 2026Software / SaaS
Open Text CorpOTEX
8-K · Items 2.02, 8.01 — Results of operations
OpenText reported Q1 FY2027 results with core revenue growth of 2.4% YoY and core cloud revenue growth of 11.2% YoY. Company completed $1.0B debt refinancing, paid down $300M debt, and declared $0.28/share dividend. Net income margin 12.6%, Adjusted EBITDA margin 35.8%.
The shares became cheaper on AIR's value read.
Progress is running ahead of attention.
The price trend strengthened.
8-KFiled 5 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Q3 2026 results in-line with guidance but full-year outlook worsened. Middle East conflict caused supply chain disruptions, raw material cost headwinds ($15-20M), and weaker demand. Full-year free cash flow revised to use $25-50M vs. prior expectations.
No notable change in AIR's read.
10-QFiled 5 Nov 2026Industrials
Solventum CorpSOLV
Quarterly report (10-Q), period ending 30 Sep 2026
More of the market is starting to notice.
Progress is running ahead of attention.
The price trend strengthened.
8-KFiled 5 Nov 2026Semiconductors
Nlight, Inc.LASR
8-K · Item 2.02 — Results of operations
Q3 2026 revenue of $73.8M exceeded guidance high-end (+10.5% YoY). Gross margin expanded to 33.1% (vs. 31.1% prior year). Adjusted EBITDA surged 55.4% to $11.1M. Defense demand remains strong; Q4 guidance $84–90M despite $15M supply-chain delay to H1 2027.
More of the market is starting to notice.
The shares became dearer on AIR's value read.
The price trend strengthened.
10-QFiled 5 Nov 2026All industries
U S Physical Therapy Inc /NVUSPH
Quarterly report (10-Q), period ending 30 Sep 2026
The shares became dearer on AIR's value read.
The gap narrowed — attention is catching up.
The price trend strengthened.
8-KFiled 5 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Centuri reported Q3 2026 record revenue of $1.2B (+40% YoY) and gross profit of $113.4M (+45% YoY) with margin expansion to 9.5%. Net income surged 1,174% to $26.9M. Company raised 2026 guidance and provided 2027 targets of mid-teens revenue growth and 8.5–9% gross margin.
Progress is running ahead of attention.
The price trend weakened.
8-KFiled 5 Nov 2026All industries
Skyward Specialty Insurance Group, Inc.SKWD
8-K · Item 2.02 — Results of operations
Q3 2026 results show managed premiums up 12.5% YoY, fee-generating premiums up 18.4%, combined ratio of 89.9%, and nine-month operating ROE of 20.4%. Book value per share increased 15.3% since year-end.
Progress is running ahead of attention.
8-KFiled 5 Nov 2026All industries
Amn Healthcare Services IncAMN
8-K · Item 2.02 — Results of operations
Q3 2026 revenue of $717M (+13% YoY) and adjusted EPS of $1.16 (+199% YoY) exceeded guidance. Travel nurse/allied segment grew 27% YoY. Q4 guidance implies 10-12% revenue decline YoY, primarily due to labor disruption normalization.
Market attention has faded.
The shares became cheaper on AIR's value read.
Progress is running ahead of attention.
The price trend weakened.
10-QFiled 5 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
The shares became cheaper on AIR's value read.
The price trend weakened.
8-KFiled 5 Nov 2026Software / SaaS
8-K · Item 2.02 — Results of operations
BlackLine reported Q3 2026 revenue of $193.4M (+8.5% YoY), GAAP operating margin of 8.6% (vs. 4.3% prior year), and non-GAAP operating margin of 25.9%. RPO grew 14.3% to $1.1B. Dollar-based NRR at 103%. Company raised full-year guidance.
The shares became cheaper on AIR's value read.
Progress is running ahead of attention.
The price trend weakened.
8-KFiled 5 Nov 2026Software / SaaS
AvePoint, Inc.AVPT
8-K · Item 2.02 — Results of operations
AvePoint reported Q3 2026 SaaS revenue of $105.5M (+26% YoY), total revenue $131.1M (+19% YoY), and ARR of $495.1M (+27% YoY). GAAP operating margin expanded to 8.7%. Company raised full-year 2026 guidance for ARR, revenue, and non-GAAP operating income.
The shares became dearer on AIR's value read.
Progress is running ahead of attention.
8-KFiled 5 Nov 2026All industries
Wynn Resorts LtdWYNN
8-K · Items 2.02, 8.01 — Results of operations
The shares became dearer on AIR's value read.
The gap narrowed — attention is catching up.
The price trend strengthened.
10-QFiled 5 Nov 2026All industries
Wynn Resorts LtdWYNN
Quarterly report (10-Q), period ending 30 Sep 2026
The shares became dearer on AIR's value read.
The gap narrowed — attention is catching up.
The price trend strengthened.
10-QFiled 5 Nov 2026All industries
Quarterly report (10-Q), period ending 3 Oct 2026
More of the market is starting to notice.
Progress is running ahead of attention.
The price trend strengthened.
10-QFiled 5 Nov 2026Software / SaaS
Certara, Inc.CERT
Quarterly report (10-Q), period ending 30 Sep 2026
More of the market is starting to notice.
The shares became dearer on AIR's value read.
Progress is running ahead of attention.
The price trend strengthened.
10-QFiled 5 Nov 2026Software / SaaS
Coursera, Inc.COUR
Quarterly report (10-Q), period ending 30 Sep 2026
The gap narrowed as the filings read less positively.
8-KFiled 5 Nov 2026All industries
8-K · Item 2.02 — Results of operations
TIC Solutions reported Q3 2026 record revenue of $639.6M (+35% YoY, +12.5% combined basis), net loss of $11.1M, Adjusted EBITDA of $107.2M (+39% YoY), record backlog of $1.29B (+23% YoY), and raised full-year 2026 revenue guidance.
More of the market is starting to notice.
Progress is running ahead of attention.
The price trend strengthened.
10-QFiled 5 Nov 2026Software / SaaS
Snap IncSNAP
Quarterly report (10-Q), period ending 30 Sep 2026
The shares became cheaper on AIR's value read.
Progress is running ahead of attention.
The price trend weakened.
10-QFiled 5 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
The price trend weakened.
10-QFiled 5 Nov 2026Industrials
Kratos Defense & Security Solutions, Inc.KTOS
Quarterly report (10-Q), period ending 27 Sep 2026
The shares became cheaper on AIR's value read.
Progress is running ahead of attention.
The price trend weakened.
10-QFiled 5 Nov 2026All industries
Wendy's CoWEN
Quarterly report (10-Q), period ending 27 Sep 2026
The filings read less positively.
More of the market is starting to notice.
The price trend strengthened.
Sun 22 Nov
CAPR · Capricor Therapeutics, Inc. · Regulatory date
As stated in the filing: “Deramiocel Biologics License Application (BLA) for Duchenne muscular dystrophy (DMD) under FDA review; PDUFA target action date of November 22, 2026 ●”
Announced by the company in 8-K on 10 Nov 2026
DYN · Dyne Therapeutics, Inc. · Regulatory date
As stated in the filing: “Capricor Therapeutics’ BLA for its cell therapy deramiocel is currently under FDA review with a PDUFA date of November 22, 2026.”
Announced by the company in 10-Q on 5 Nov 2026
SVRA · Savara Inc · Regulatory date
As stated in the filing: “The FDA determined that the Company’s responses to recent information requests by the Agency during its review constituted a major amendment to the BLA, resulting in a three-month extension of the Prescription Drug User Fee Act ("PDUFA") target action date to November 22, 2026.”
Announced by the company in 10-Q on 9 Nov 2026
Fri 27 Nov
BBIO · BridgeBio Pharma, Inc. · Regulatory date
As stated in the filing: “The first participant was dosed in ASCEND-ATTR, the Phase 3b/4 study to prospectively test disease reversal with Attruby - BBP-418 for LGMD2I/R9 has a November 27, 2026 PDUFA date, with Priority Review.”
Announced by the company in 8-K on 29 Oct 2026
Mon 30 Nov
COGT · Cogent Biosciences, Inc. · Regulatory date
As stated in the filing: “Potential FDA approval of bezuclastinib in GIST – PDUFA date of November 30, 2026 •”
Announced by the company in 8-K on 5 Nov 2026
JBIO · Jade Biosciences, Inc. · Regulatory date
As stated in the filing: “The FDA has also accepted a Biologics License Application for accelerated approval of povetacicept in IgAN, with a Prescription Drug User Fee Act target action date of November 30, 2026.”
Announced by the company in 10-Q on 13 Nov 2026
Wed 2 Dec
ARE · Alexandria Real Estate Equities, Inc. · Investor day
As stated in the filing: “We expect to introduce 2027 guidance and related assumptions at our Investor Day on December 2, 2026, consistent with our historical practice.”
Announced by the company in 8-K on 27 Apr 2026
Thu 3 Dec
EXEL · Exelixis, Inc. · Regulatory date
As stated in the filing: “In February 2026, we announced that the FDA had accepted our NDA and assigned a standard review, with a Prescription Drug User Fee Act (PDUFA) target action date of December 3, 2026.”
Announced by the company in 10-Q on 29 Oct 2026
Tue 8 Dec
GPC · Genuine Parts Co · Investor day
As stated in the filing: “In addition, the Company announced that both Global Automotive and Global Industrial will host separate investor days on December 8, 2026 and December 9, 2026, respectively.”
Announced by the company in 8-K on 9 Sep 2026
LGND · Ligand Pharmaceuticals Inc · Investor day
As stated in the filing: “Ligand will provide an updated 5-year outlook during the Company’s Investor Day on December 8, 2026.”
Announced by the company in 8-K on 14 Jul 2026
Wed 9 Dec
GPC · Genuine Parts Co · Investor day
As stated in the filing: “Investor Days GPC and Motion will host separate investor days in New York City, with GPC’s Investor Day scheduled for December 8, 2026, and Motion’s Investor Day scheduled for December 9, 2026.”
Announced by the company in 8-K on 9 Sep 2026
Sat 12 Dec
ANAB · Anaptysbio, Inc · Regulatory date
As stated in the filing: “FDA target action date (PDUFA) of December 12, 2026, for Quimilza in generalized pustular psoriasis (GPP) GSK and Tesaro Litigation Update •”
Announced by the company in 8-K on 12 Nov 2026
Thu 17 Dec
CORT · Corcept Therapeutics Inc · Regulatory date
As stated in the filing: “Relacorilant for patients with Cushing’s syndrome – Resubmitted New Drug Application Prescription Drug User Fee Act (PDUFA) date of December 17, 2026 “The ADA and EASD consensus statement is an important advance for the many patients whose difficult-to-control hyperglycemia is a manifestation of undiagnosed Cushing’s syndrome,” said Bill Guyer, PharmD, Corcept’s Chief Development Officer.”
Announced by the company in 8-K on 3 Nov 2026
Mon 23 Nov
MATW · Matthews International Corp · All industries
Annual results due — last year filed 21 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue down 30%, net income turned to a loss
AIR's current read: News flow Balanced, Gap Low · 0
Tue 24 Nov
BLBD · Blue Bird Corp · Industrials
Annual results due — last year filed 24 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue up 30%, net income up 408%
AIR's current read: News flow Balanced, Gap Very high · 82
PFLT · PennantPark Floating Rate Capital Ltd. · All industries
Annual results due — last year filed 24 Nov 2025
AIR's current read: News flow Balanced, Gap Very high · 71
Wed 25 Nov
AMTM · Amentum Holdings, Inc. · All industries
Annual results due — last year filed 25 Nov 2025
Last quarter (Q3 2025, against a year earlier): revenue up 66%, net income turned positive
AIR's current read: News flow Balanced, Gap Low · 4
ARMK · Aramark · All industries
Annual results due — last year filed 25 Nov 2025
Last quarter (Q3 2025, against a year earlier): revenue up 6%, net income up 23%
AIR's current read: News flow Balanced, Gap Medium · 10
CASH · Pathward Financial, Inc. · Banks
Annual results due — last year filed 25 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue down 3%, net income down 31%
AIR's current read: News flow Balanced, Gap Low · 0
CLSK · Cleanspark, Inc. · Banks
Annual results due — last year filed 25 Nov 2025
Last quarter (Q3 2024, against a year earlier): revenue up 129%, net loss widened
AIR's current read: News flow Balanced, Gap Very high · 54
GAP · Gap Inc · All industries
Quarterly results due — last year filed 25 Nov 2025
Last quarter (Q3 2024, against a year earlier): revenue down 7%, net income down 23%
AIR's current read: News flow Balanced, Gap Low · 3
ROAD · Construction Partners, Inc. · All industries
Annual results due — last year filed 25 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue up 28%, net income up 35%
AIR's current read: News flow Balanced, Gap Low · 7
SJM · J M SMUCKER Co · All industries
Quarterly results due — last year filed 25 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue up 7%, net loss widened
AIR's current read: News flow Balanced, Gap Low · 7
SMG · Scotts Miracle-Gro Co · All industries
Annual results due — last year filed 25 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue up 1%, net income down 25%
AIR's current read: News flow Balanced, Gap Medium · 12
SMTC · Semtech Corp · Semiconductors
Quarterly results due — last year filed 25 Nov 2025
Last quarter (Q1 2027, against a year earlier): revenue up 16%, net income up 37%
AIR's current read: News flow Balanced, Gap Low · 0
TFSL · TFS Financial CORP · Banks
Annual results due — last year filed 25 Nov 2025
Last quarter (Q1 2019, against a year earlier): net income up 4%
AIR's current read: News flow Balanced, Gap Medium · 23
Fri 27 Nov
ATKR · Atkore Inc. · Industrials
Annual results due — last year filed 26 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue up 8%, net income down 98%
AIR's current read: News flow Balanced, Gap Low · 0
BJ · BJ's Wholesale Club Holdings, Inc. · All industries
Quarterly results due — last year filed 26 Nov 2025
Last quarter (Q2 2027, against a year earlier): revenue up 16%, net income up 15%
AIR's current read: News flow Balanced, Gap Medium · 18
CENT · Central Garden & Pet Co · All industries
Annual results due — last year filed 26 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue down 8%, net income down 5%
AIR's current read: News flow Balanced, Gap Low · 1
CFFN · Capitol Federal Financial, Inc. · Banks
Annual results due — last year filed 26 Nov 2025
Last quarter (Q3 2020, against a year earlier): net income down 15%
AIR's current read: News flow Balanced, Gap Medium · 10
JJSF · J&J Snack Foods Corp · All industries
Annual results due — last year filed 26 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue down 6%, net income down 20%
AIR's current read: News flow Balanced, Gap Low · 0
PD · PagerDuty, Inc. · Software / SaaS
Quarterly results due — last year filed 26 Nov 2025
Last quarter (Q1 2027, against a year earlier): revenue up 1%, net income turned positive
AIR's current read: News flow Balanced, Gap Low · 0
SPH · Suburban Propane Partners Lp · All industries
Annual results due — last year filed 26 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue unchanged, net loss widened
AIR's current read: News flow Balanced, Gap Medium · 21
UTI · Universal Technical Institute Inc · All industries
Annual results due — last year filed 26 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue up 7%, net income down 79%
AIR's current read: News flow Balanced, Gap Very high · 57
Mon 30 Nov
SNEX · StoneX Group Inc. · All industries
Annual results due — last year filed 28 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue up 15%, net income up 102%
AIR's current read: News flow Balanced, Gap Very high · 52
Tue 1 Dec
ESE · Esco Technologies Inc · Industrials
Annual results due — last year filed 1 Dec 2025
Last quarter (Q3 2026, against a year earlier): revenue up 14%, net income up 26%
AIR's current read: News flow Balanced, Gap Very high · 97
Wed 2 Dec
ASAN · Asana, Inc. · Software / SaaS
Quarterly results due — last year filed 2 Dec 2025
Last quarter (Q2 2027, against a year earlier): revenue up 10%, net loss narrowed
AIR's current read: News flow Balanced, Gap Low · 0
UNFI · United Natural Foods Inc · All industries
Quarterly results due — last year filed 2 Dec 2025
AIR's current read: News flow Balanced, Gap Low · 0
VSTS · Vestis Corp · All industries
Annual results due — last year filed 2 Dec 2025
Last quarter (Q3 2025, against a year earlier): revenue down 4%, net income turned to a loss
AIR's current read: News flow Balanced, Gap Low · 1
Thu 3 Dec
BOX · Box Inc · Software / SaaS
Quarterly results due — last year filed 3 Dec 2025
Last quarter (Q2 2027, against a year earlier): revenue up 9%, net income up 43%
AIR's current read: News flow Balanced, Gap Low · 1
CRWD · CrowdStrike Holdings, Inc. · Software / SaaS
Quarterly results due — last year filed 3 Dec 2025
Last quarter (Q1 2027, against a year earlier): revenue up 26%, net income turned positive
AIR's current read: News flow Balanced, Gap Low · 5
HQY · Healthequity, Inc. · All industries
Quarterly results due — last year filed 3 Dec 2025
Last quarter (Q2 2027, against a year earlier): revenue up 8%, net income up 10%
AIR's current read: News flow Balanced, Gap Low · 0
KSS · KOHLS Corp · All industries
Quarterly results due — last year filed 3 Dec 2025
Last quarter (Q3 2024, against a year earlier): revenue down 5%, net income down 39%
AIR's current read: News flow Balanced, Gap Medium · 11
MEI · Methode Electronics Inc · Industrials
Quarterly results due — last year filed 3 Dec 2025
AIR's current read: News flow Balanced, Gap Low · 0
NCNO · nCino, Inc. · Software / SaaS
Quarterly results due — last year filed 3 Dec 2025
Last quarter (Q1 2027, against a year earlier): revenue up 11%, net income up 145%
AIR's current read: News flow Balanced, Gap Low · 5
THO · Thor Industries Inc · Industrials
Quarterly results due — last year filed 3 Dec 2025
Last quarter (Q4 2026, against a year earlier): revenue down 8%, net income down 68%
AIR's current read: News flow Balanced, Gap Low · 4
Fri 4 Dec
AGX · Argan Inc · All industries
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q2 2027, against a year earlier): revenue up 62%, net income up 51%
AIR's current read: News flow Balanced, Gap Low · 9
AMBA · Ambarella Inc · Semiconductors
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q2 2027, against a year earlier): revenue up 13%, net loss narrowed
AIR's current read: News flow Balanced, Gap Low · 7
BF-B · Brown Forman Corp · All industries
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q1 2027, against a year earlier): revenue down 1%, net income up 4%
AIR's current read: News flow Balanced, Gap Low · 0
CXM · Sprinklr, Inc. · Software / SaaS
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q2 2027, against a year earlier): revenue up 1%, net income down 44%
AIR's current read: News flow Balanced, Gap Low · 9
DCI · DONALDSON Co INC · All industries
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q4 2026, against a year earlier): revenue up 8%, net income up 13%
AIR's current read: News flow Balanced, Gap Low · 9
FIVE · Five Below, Inc · All industries
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q3 2024, against a year earlier): revenue up 14%, net income down 10%
AIR's current read: News flow Balanced, Gap High · 27
GWRE · Guidewire Software, Inc. · Software / SaaS
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q3 2026, against a year earlier): revenue up 27%, net income down 64%
AIR's current read: News flow Balanced, Gap High · 44
NTNX · Nutanix, Inc. · Software / SaaS
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q3 2026, against a year earlier): revenue up 10%, net income up 14%
AIR's current read: News flow Balanced, Gap Medium · 22
REX · REX AMERICAN RESOURCES Corp · All industries
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q2 2027, against a year earlier): revenue up 6%, net income up 336%
AIR's current read: News flow Balanced, Gap Low · 0
SAIC · Science Applications International Corp · Software / SaaS
Quarterly results due — last year filed 4 Dec 2025
AIR's current read: News flow Balanced, Gap High · 39
SWBI · Smith & Wesson Brands, Inc. · Industrials
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q1 2027, against a year earlier): revenue up 32%, net income turned positive
AIR's current read: News flow Balanced, Gap Very high · 87
TITN · Titan Machinery Inc. · All industries
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q2 2027, against a year earlier): revenue down 9%, net loss widened
AIR's current read: News flow Balanced, Gap Low · 0
Expected dates come from each company's filing history. They are not forecasts, and companies move them.
Sign in to follow companies
Follow a company and its filings show up here.
Sign inResearch, not tips. Filings come from SEC EDGAR; AIR's read is recomputed every trading day. A price move is shown as a fact beside a filing, never as the reason it is listed.